Laronde Stock
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
Sign up today and learn more about Laronde Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Laronde Stock
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.
Funding History
| May 2021 | $50.0M |
|---|---|
| August 2021 | $440M |
Management
Co-founder and Chairman of the Board
Noubar Afeyan
Co-founder & Board of Directors
Avak Kahvejian
Board of Directors
Noubar Afeyan
Chief Operating Officer
Tej Pavoor
Chief Technology Officer
Vadim Dudkin
Head of Manufacturing
Tushar Misra
CEO
Diego Miralles
Chief Scientific Officer
Jesper Gromada
Press
biopharmadive - Dec, 20 2023
Alltrna raises $109M for 'transfer RNA' drug visionbiopharmadive - Dec, 20 2023
Laronde, Senda Biosciences merge to create new Flagship ...fiercebiotech - Oct, 20 2023
Flagship's embattled Laronde sets sail with Senda in mergerstatnews - Jun, 19 2023
Listen: Biogen’s messy board, Laronde’s data problem, & the downside of a boombizjournals - May, 11 2023
The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partnerEquityZen Recognized As:
